Search

Mark O Goodarzi

from Los Angeles, CA
Age ~53
Get Report
Also known as:
Mark Dr Goodarzi, Mark Omid Goodarzi, Mark Te Goodarzi, Mark C Goodarzi, Mark Eskandari, Mark I
Phone and address:
236 Lucerne Blvd, Los Angeles, CA 90004
(323) 906-1101
Related to:
Shahin I Goodarzi, 75Armin Goodarzi, 43Marsha PontrelliParham Ilampour, 39Sam Ilampour, 53
Connected to:
Elham Goodarzi, 45John Goodarzi, 66Barbara M Goodas, 73Jennifer Goodballet, 32Aida Goodbarian, 61David A Goodbary, 58James R Goodbar, 91John C Goodbar, 93Staci J Goodbar, 54Teresa E Goodbar, 62

Mark Goodarzi Phones & Addresses

  • 236 Lucerne Blvd, Los Angeles, CA 90004 (323) 906-1101
  • 1418 Butler Ave, Los Angeles, CA 90025 (310) 477-5134
  • 1447 Saltair Ave, Los Angeles, CA 90025 (310) 477-5134
  • Pasadena, CA
  • San Francisco, CA
  • Tampa, FL

Work

Company: Los Angeles Office Address: 8700 Beverly Blvd, Los Angeles, CA 90048 Phones: (800) 233-2771 (310) 659-3928

Education

School / High School: University of California At San Francisco 1997

Languages

English • Spanish

Awards

Healthgrades Honor Roll

Ranks

Certificate: Diabetes, Metabolism & Endocrinology, 2002

Specialities

Endocrinology, Diabetes & Metabolism

Professional Records

Medicine Doctors

Mark Goodarzi Photo 1

Dr. Mark O Goodarzi, Los Angeles CA - MD (Doctor of Medicine)

View page
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
Los Angeles Office
8700 Beverly Blvd, Los Angeles, CA 90048
(800) 233-2771 (Phone), (310) 659-3928 (Fax)

Cedars-Sinai Med Ctr END/RHU
8723 Alden Dr Suite 298, Los Angeles, CA 90048
(310) 423-3870 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 2002
Internal Medicine, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Spanish
Education:
Medical School
University of California At San Francisco
Graduated: 1997
Medical School
U Calif Mc
Graduated: 1997
Medical School
University Of California-Los Angeles
Graduated: 1997
Mark Goodarzi Photo 2

Mark Omid Goodarzi, West Hollywood CA

View page
Specialties:
Internist
Address:
8700 Beverly Blvd, West Hollywood, CA 90048

Business Records

Name / Title
Company / Classification
Phones & Addresses
Mark Omid Goodarzi
Mark Goodarzi MD,PHD
Endocrinologist · Internist
8700 Beverly Blvd, Los Angeles, CA 90048
(310) 423-4774
Mark O. Goodarzi
Endocrinology
CEDARS-SINAI MEDICAL CENTER
General Hospital Anesthesiology · General Hospital · Medical Doctor's Office · Nonclassifiable Establishments · General Hospital Noncommercial Research Organization · Noncommercial Research Organization · Colon Care · Surgeons
8700 Beverly Blvd, Los Angeles, CA 90048
9701 W Pico Blvd, Los Angeles, CA 90035
8797 Beverly Blvd, Los Angeles, CA 90048
PO Box 17559, Beverly Hills, CA 90209
(310) 423-3277, (310) 423-0448, (310) 423-8780, (310) 423-5841

Publications

Us Patents

Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance, Coronary Artery Disease And Other Phenotypes

View page
US Patent:
8178294, May 15, 2012
Filed:
Nov 28, 2006
Appl. No.:
11/564243
Inventors:
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Hockessin DE, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 1/68
C12P 19/34
US Classification:
435 61, 435 912
Abstract:
Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a human subject for certain biological conditions, which may be related to coronary artery disease.

Lipoprotein Lipase And Its Effect On Statin Treatments

View page
US Patent:
20100130600, May 27, 2010
Filed:
Mar 28, 2008
Appl. No.:
12/594143
Inventors:
Mark O. Goodarzi - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Maren T. Scheuner - Manhattan Beach CA, US
Xiuqing Guo - Santa Monica CA, US
Prediman K. Shah - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
A61K 31/366
US Classification:
514460, 435 6
Abstract:
The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus.

Methods Of Diagnosing Insulin Resistance And Sensitivity

View page
US Patent:
20120088245, Apr 12, 2012
Filed:
Oct 30, 2009
Appl. No.:
13/126695
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Mark O. Goodarzi - Los Angeles CA, US
Leslie Raffel - Los Angeles CA, US
Thomas A. Buchanan - Los Angeles CA, US
Anny Xiang - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 612
Abstract:
Methods of diagnosing susceptibility to metabolic insulin resistance and other related conditions are disclosed. The method provides means of diagnosing susceptibility to insulin resistance in Hispanic Americans by determining the presence of a risk haplotype at the LPL locus, the LPIN1 locus, and/or elevated levels of gamma-glutamyl transferase.

Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance And Coronary Artery Disease

View page
US Patent:
7141373, Nov 28, 2006
Filed:
Jun 16, 2003
Appl. No.:
10/463301
Inventors:
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68
C12P 19/34
C07H 21/04
US Classification:
435 6, 435 912, 536 232, 536 235
Abstract:
Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a Mexican-American human subject for developing insulin resistance and methods of detecting a lower than normal risk in a Mexican-American human subject for developing insulin resistance or coronary artery disease.

Methods For Prognosing Heart Transplant

View page
US Patent:
20170240965, Aug 24, 2017
Filed:
Feb 22, 2017
Appl. No.:
15/439830
Inventors:
- Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Jon Kobashigawa - Playa Del Rey CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 1/68
Abstract:
Provided herein is a method, comprising: obtaining a sample from the subject; assaying the sample to detect the risk alleles at one or more SNPs; calculating a genetic risk score (GRS) of the subject based on the detected risk alleles at the one or more SNPs; determining that the subject has an increased likelihood of poor prognosis if the GRS of the subject is above the mean or median GRS of the sample population or determining that the subject has an increased likelihood of good prognosis if the GRS of the subject is the same as or above the mean or median GRS of the sample population; and selecting a therapy if poor prognosis is determined.
Control profile
Mark O Goodarzi from Los Angeles, CA, age ~53 Get Report